LUC00072I2 - Niraparib ou un sel pharmaceutiquement acceptable, stéréoisomère ou tautomère de celui-ci, notamment le tosylate ou un hydrate, particulièrement le tosylate monohydraté - Google Patents

Niraparib ou un sel pharmaceutiquement acceptable, stéréoisomère ou tautomère de celui-ci, notamment le tosylate ou un hydrate, particulièrement le tosylate monohydraté Download PDF

Info

Publication number
LUC00072I2
LUC00072I2 LU00072C LUC00072C LUC00072I2 LU C00072 I2 LUC00072 I2 LU C00072I2 LU 00072 C LU00072 C LU 00072C LU C00072 C LUC00072 C LU C00072C LU C00072 I2 LUC00072 I2 LU C00072I2
Authority
LU
Luxembourg
Prior art keywords
tosylate
pharmaceutically acceptable
niraparib
tautomer
stereoisomer
Prior art date
Application number
LU00072C
Other languages
English (en)
French (fr)
Original Assignee
Msd Italia Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37809722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LUC00072(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Msd Italia Srl filed Critical Msd Italia Srl
Publication of LUC00072I2 publication Critical patent/LUC00072I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LU00072C 2007-01-10 2018-05-03 Niraparib ou un sel pharmaceutiquement acceptable, stéréoisomère ou tautomère de celui-ci, notamment le tosylate ou un hydrate, particulièrement le tosylate monohydraté LUC00072I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0700432.8A GB0700432D0 (en) 2007-01-10 2007-01-10 Therapeutic compounds

Publications (1)

Publication Number Publication Date
LUC00072I2 true LUC00072I2 (fr) 2018-07-04

Family

ID=37809722

Family Applications (1)

Application Number Title Priority Date Filing Date
LU00072C LUC00072I2 (fr) 2007-01-10 2018-05-03 Niraparib ou un sel pharmaceutiquement acceptable, stéréoisomère ou tautomère de celui-ci, notamment le tosylate ou un hydrate, particulièrement le tosylate monohydraté

Country Status (21)

Country Link
CN (1) CN101578279B (pt)
AT (1) ATE502933T1 (pt)
CR (1) CR10910A (pt)
DE (1) DE602008005711D1 (pt)
DK (2) DK2336120T3 (pt)
ES (3) ES2728199T3 (pt)
GB (1) GB0700432D0 (pt)
HN (1) HN2009001260A (pt)
HU (1) HUE044513T2 (pt)
LT (1) LT2805945T (pt)
LU (1) LUC00072I2 (pt)
ME (1) ME03481B (pt)
MY (1) MY147789A (pt)
NI (1) NI200900135A (pt)
NZ (1) NZ578256A (pt)
PE (1) PE20081558A1 (pt)
PT (3) PT2109608E (pt)
SI (2) SI2109608T1 (pt)
TW (1) TWI528961B (pt)
UA (1) UA97658C2 (pt)
ZA (1) ZA200903898B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106496187A (zh) * 2016-09-14 2017-03-15 陕西科技大学 一种制备PARP抑制剂Niraparib的合成方法
CN106432187A (zh) * 2016-09-17 2017-02-22 青岛云天生物技术有限公司 2‑[4‑(‑3‑哌啶基)苯基]‑2h‑吲唑‑7‑甲酰胺的手性拆分方法
CN106432188A (zh) * 2016-09-17 2017-02-22 青岛辰达生物科技有限公司 一种抗癌药2‑[4‑((3s)‑3‑哌啶基)苯基]‑2h‑吲唑‑7‑甲酰胺的制备方法
CN106632244A (zh) * 2016-09-30 2017-05-10 陕西科技大学 一种制备抗癌药物Niraparib的新型合成方法
CN106467513A (zh) * 2016-09-30 2017-03-01 陕西科技大学 一种制备Niraparib的合成方法
CN108201537A (zh) * 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 一种尼拉帕尼缓控释药物组合物及其用途
KR20190130625A (ko) * 2017-03-27 2019-11-22 테사로, 인코포레이티드 니라파립 제제
CN109081828B (zh) * 2017-06-14 2021-03-26 上海时莱生物技术有限公司 聚(adp-核糖)聚合酶抑制剂、制备方法及用途
CA3076907A1 (en) 2017-09-26 2019-04-04 Tesaro, Inc. Niraparib formulations
CN108084157A (zh) * 2018-02-12 2018-05-29 安庆奇创药业有限公司 一种尼拉帕尼的合成方法
CN108203404A (zh) * 2018-03-02 2018-06-26 上海博邦医药科技有限公司 (r)-3-苯基哌啶或/和(s)-3-苯基哌啶以及尼拉帕尼的手性中间体的合成方法
US20240016775A1 (en) 2020-02-24 2024-01-18 Fukang (Shanghai) Health Technology Co., Ltd Anti-coronavirus application of poly adp ribose polymerase inhibitor
CN115611860B (zh) * 2021-07-13 2024-06-11 上海博璞诺科技发展有限公司 合成尼拉帕尼的方法

Also Published As

Publication number Publication date
LT2805945T (lt) 2019-06-25
TW200836731A (en) 2008-09-16
ATE502933T1 (de) 2011-04-15
PT2109608E (pt) 2011-05-30
NZ578256A (en) 2011-12-22
GB0700432D0 (en) 2007-02-21
CN101578279A (zh) 2009-11-11
SI2109608T1 (sl) 2011-07-29
DE602008005711D1 (de) 2011-05-05
MY147789A (en) 2013-01-31
CR10910A (es) 2010-01-19
HUE044513T2 (hu) 2019-10-28
ES2509115T3 (es) 2014-10-17
ME03481B (me) 2020-01-20
UA97658C2 (ru) 2012-03-12
ZA200903898B (en) 2010-04-28
PT2336120E (pt) 2014-10-01
DK2109608T3 (da) 2011-07-11
HN2009001260A (es) 2012-03-26
PE20081558A1 (es) 2008-10-30
ES2728199T3 (es) 2019-10-22
PT2805945T (pt) 2019-06-06
SI2336120T1 (sl) 2014-10-30
NI200900135A (es) 2010-08-30
ES2362214T3 (es) 2011-06-29
DK2336120T3 (da) 2014-10-06
TWI528961B (zh) 2016-04-11
CN101578279B (zh) 2013-07-17

Similar Documents

Publication Publication Date Title
LUC00072I2 (fr) Niraparib ou un sel pharmaceutiquement acceptable, stéréoisomère ou tautomère de celui-ci, notamment le tosylate ou un hydrate, particulièrement le tosylate monohydraté
MX2009007200A (es) Indazoles sustituidos con amida como inhibidores de poli(adp-ribosa)polimerasa (parp).
MX2010005070A (es) Derivados de piridazinona como inhibidores de parp.
WO2007138351A3 (en) Pyridinone and pyridazinone derivatives as inhibitors of poly(adp-ribose)polymerase (parp)
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
MX2012002179A (es) Compuestos heterociclicos de oxima.
RS54030B1 (en) PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR CANCER TREATMENT
MX346186B (es) Inhibidores de proteina cinasas.
WO2010054278A3 (en) Compounds for the treatment of inflammatory disorders
BR112015002293A2 (pt) di-hidropiridona pi como inibidores do fator xia
WO2008017883A3 (en) 4-oxo-4,5-dihydropyrrolo[1,2-a] quinoxaline derivatives as inhibitors of poly(adp-ribose)polymerase(parp)
BR112012008546A2 (pt) derivados de sulfóxido para o tratamento de tumor
MA32727B1 (fr) Pyrazolylaminopyridines au titre d'inhibiteurs de fak
MX2012007582A (es) Compuestos de 4-fenoxi-nicotinamida o 4-fenoxi-pirimidina-5-carbox amida.
WO2011147951A8 (en) Cycloamino derivatives as gpr119 agonists
MY150745A (en) Isoserine derivatives for use as coagulation factor ixa inhibitors
GB201114389D0 (en) Novel compounds
PH12015500418A1 (en) Pyridine derivative and medicine
MX2014005538A (es) 1-piridazinil-hidroxiimino-3-fenil-propanos como agonistas de proteina g-receptor acoplado a acido biliar 1 (gpbar1).